Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Melanoma/Skin Cancer
•
Dermatology
Are there certain patient characteristics that drive you to recommend intralesional 5-FU or MTX for a large SCC on the back?
Related Questions
How would you approach the radiation treatment of multiple recurrent lentigo maligna on the sole of the foot in an active patient not desiring further surgery?
Would you favor radiation or immune modulating treatment like imiquimod to treat an uncomplicated basal cell carcinoma on the nose in an elderly patient for whom you'd like to avoid surgery?
What criteria are used to select patients who have locally advanced BCC patients for treatment with sonidegib?
How would you manage BCC to the left cheek after only half of a radiation course was completed three months ago and non-operative management is preferred?
How would you manage a large area of multiple, recurrent cutaneous squamous cell carcinomas of the scalp with ulcerations and non-healing areas despite cryotherapy, multiple Mohs procedures, and 5-FU?
What biologics would you use in a patient with rheumatoid arthritis who developed multiple basal cell carcinomas requiring Mohs surgery while on a TNF-inhibitor and did not respond to rituximab?
Have you considered intralesional cempilumab for locally advanced NMSC/KCs prior to surgery?
What factors do you weigh most heavily in the selection of radiotherapy versus topical treatments for lentigo maligna in a patient who is not a surgical candidate?
What is the recommended approach for systemic therapy in a patient with metastatic cutaneous squamous cell carcinoma with active autoimmune disease (dermatomyositis)?
What patient characteristics or clinical scenarios guide the decision in performing slow Mohs procedures?
